Protecting Our Pharmaceutical Supply Chain from China Act of 2020

Hozzl · 2022-02-08T23:15:31Z

Explore the details of Senate Bill 3537 Protecting Our Pharmaceutical Supply Chain from China Act of 2020 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

2/8/2022, 11:15 PM

Congressional Summary of S 3537

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 3537

Bill S 3537 is currently in the status of Bill Introduced since March 19, 2020. Bill S 3537 was introduced during Congress 116 and was introduced to the Senate on March 19, 2020. Bill S 3537's most recent activity was Read twice and referred to the Committee on Finance. as of March 19, 2020

Bipartisan Support of Bill S 3537

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 3537

Primary Policy Focus

Health

Potential Impact Areas

- Asia

- Business expenses

- China

- Drug safety, medical device, and laboratory regulation

- Government information and archives

- Health care costs and insurance

- Health programs administration and funding

- Health technology, devices, supplies

- Income tax deductions

- Manufacturing

- Military medicine

- Military procurement, research, weapons development

- Prescription drugs

- Public contracts and procurement

- Trade restrictions

- Veterans' medical care

Alternate Title(s) of Bill S 3537

Protecting Our Pharmaceutical Supply Chain from China Act of 2020

A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in China, and for other purposes.